1902, Secretin and Fischer: A Physician’s Read on the Birth of Peptide Science
How a denervated loop of gut and a Berlin flask launched peptide science in 1902: the experiment, the 68-year path to secretin’s sequence, the limits, and why it still matters for GLP-1 therapy.
Optogenetics Wins the 2026 Nobel: My Read on the Discovery, the First Patient and the Limits
From an algal light sensor to millisecond control of neurons and one partially restored patient: what the 2026 Nobel work in optogenetics shows, what it can’t do yet, and why clinicians should care.
Frailty Should Not Preclude Semaglutide? My Read of the SELECT Frailty Analysis
A post hoc analysis of SELECT applied a 31-item frailty index to 17,604 adults. The heart benefit looked consistent across frailty levels. Here is what it shows, what it can’t, and how I would pair it with strength and protein.
Less Chemo, Better Results: My Read of the Blinatumomab Trial in High-Risk Childhood ALL
A randomized trial of 709 children replaced two intensive chemo cycles with blinatumomab. Here is what it shows, what it does not, and what I would ask.
One Shot, Nearly a Year of Lower Lp(a): My Honest Read of the Kylo-11 Lancet Study
A physician's close read of the first-in-human Kylo-11 trial in The Lancet: one siRNA shot lowered Lp(a) by about 53 to 97% at 48 weeks. What excites me, where I pump the brakes, and why it is worth asking for the Lp(a) lab.
More Than Half of Healthy Adults Had Silent Plaque: My Read of the REACT Study
REACT imaged the carotid, femoral and coronary arteries of adults aged 18 to 70 without known cardiovascular disease and found silent atherosclerosis in 57.1%. My read of what the study shows, what it does not, and how I plan to use it.